Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Escalating Doses of Two LEO 43204 Formulations Applied Once Daily for Two Consecutive Days on Full Face or Approximately 250 cm2 (40 in2) on the Chest in Subjects With Actinic Keratosis

NCT01922050 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT01922050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01922050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Escalating Doses of Two LEO 43204 Formulations Applied Once Daily for Two Consecutive Days on Full Face or Approximately 250 cm2 (40 in2) on the Chest in Subjects With Actinic Keratosis
Lead sponsor
LEO Pharma
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2013
Completion date
November 30, 2014
Enrollment
320 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis